Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in Patients With Vascular Ehlers-Danlos Syndrome
Phase 3
Recruiting
- Conditions
- Vascular Ehlers-Danlos Syndrome
- Interventions
- Drug: ACER-002 (celiprolol) 200 mg BIDDrug: Placebo BID
- First Posted Date
- 2022-06-27
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Acer Therapeutics Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT05432466
- Locations
- 🇺🇸
Science 37, Culver City, California, United States
Dose-ranging, PK, Safety, Efficacy Study of Osanetant in Patients With Moderate/Severe VMS Associated With Menopause
Phase 1
Completed
- Conditions
- Post-menopausal Vasomotor Symptoms
- Interventions
- Drug: ACER-801 50 mg BIDDrug: ACER-801 100 mg BIDDrug: ACER-801 200 mg BIDDrug: Placebo
- First Posted Date
- 2022-04-13
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Acer Therapeutics Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT05325775
- Locations
- 🇺🇸
Spaulding Clinical Research, West Bend, Wisconsin, United States
© Copyright 2025. All Rights Reserved by MedPath